Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome
Ectrodactyly‐ectodermal dysplasia‐clefting (EEC) syndrome is a rare autosomal dominant disease caused by mutations in the p63 gene. To date, approximately 40 different p63 mutations have been identified, all heterozygous. No definitive treatments are available to counteract and resolve the progressi...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-08-01
|
Series: | Stem Cells Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.5966/sctm.2015-0358 |
id |
doaj-dd3ca4149b594fb0b8e26b239e3a0e64 |
---|---|
record_format |
Article |
spelling |
doaj-dd3ca4149b594fb0b8e26b239e3a0e642020-11-25T01:46:43ZengWileyStem Cells Translational Medicine2157-65642157-65802016-08-01581098110510.5966/sctm.2015-0358Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting SyndromeVanessa Barbaro0Annamaria Assunta Nasti1Paolo Raffa2Angelo Migliorati3Patrizia Nespeca4Stefano Ferrari5Elisa Palumbo6Marina Bertolin7Claudia Breda8Francesco Miceli9Antonella Russo10Luciana Caenazzo11Diego Ponzin12Giorgio Palù13Cristina Parolin14Enzo Di Iorio15Fondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Biology, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Neuroscience, University of Naples Federico II, Naples, ItalyDepartment of Biology, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyEctrodactyly‐ectodermal dysplasia‐clefting (EEC) syndrome is a rare autosomal dominant disease caused by mutations in the p63 gene. To date, approximately 40 different p63 mutations have been identified, all heterozygous. No definitive treatments are available to counteract and resolve the progressive corneal degeneration due to a premature aging of limbal epithelial stem cells. Here, we describe a unique case of a young female patient, aged 18 years, with EEC and corneal dysfunction, who was, surprisingly, homozygous for a novel and de novo R311K missense mutation in the p63 gene. A detailed analysis of the degree of somatic mosaicism in leukocytes from peripheral blood and oral mucosal epithelial stem cells (OMESCs) from biopsies of buccal mucosa showed that approximately 80% were homozygous mutant cells and 20% were heterozygous. Cytogenetic and molecular analyses excluded genomic alterations, thus suggesting a de novo mutation followed by an allelic gene conversion of the wild‐type allele by de novo mutant allele as a possible mechanism to explain the homozygous condition. R311K‐p63 OMESCs were expanded in vitro and heterozygous holoclones selected following clonal analysis. These R311K‐p63 OMESCs were able to generate well‐organized and stratified epithelia in vitro, resembling the features of healthy tissues. This study supports the rationale for the development of cultured autologous oral mucosal epithelial stem cell sheets obtained by selected heterozygous R311K‐p63 stem cells, as an effective and personalized therapy for reconstructing the ocular surface of this unique case of EEC syndrome, thus bypassing gene therapy approaches. Significance This case demonstrates that in a somatic mosaicism context, a novel homozygous mutation in the p63 gene can arise as a consequence of an allelic gene conversion event, subsequent to a de novo mutation. The heterozygous mutant R311K‐p63 stem cells can be isolated by means of clonal analysis and given their good regenerative capacity, they may be used to successfully correct the corneal defects present in this unique case of ectrodactyly‐ectodermal dysplasia‐clefting syndrome.https://doi.org/10.5966/sctm.2015-0358Ectrodactyly-ectodermal dysplasia-clefting syndromeCell therapyp63MosaicismGene conversion |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vanessa Barbaro Annamaria Assunta Nasti Paolo Raffa Angelo Migliorati Patrizia Nespeca Stefano Ferrari Elisa Palumbo Marina Bertolin Claudia Breda Francesco Miceli Antonella Russo Luciana Caenazzo Diego Ponzin Giorgio Palù Cristina Parolin Enzo Di Iorio |
spellingShingle |
Vanessa Barbaro Annamaria Assunta Nasti Paolo Raffa Angelo Migliorati Patrizia Nespeca Stefano Ferrari Elisa Palumbo Marina Bertolin Claudia Breda Francesco Miceli Antonella Russo Luciana Caenazzo Diego Ponzin Giorgio Palù Cristina Parolin Enzo Di Iorio Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome Stem Cells Translational Medicine Ectrodactyly-ectodermal dysplasia-clefting syndrome Cell therapy p63 Mosaicism Gene conversion |
author_facet |
Vanessa Barbaro Annamaria Assunta Nasti Paolo Raffa Angelo Migliorati Patrizia Nespeca Stefano Ferrari Elisa Palumbo Marina Bertolin Claudia Breda Francesco Miceli Antonella Russo Luciana Caenazzo Diego Ponzin Giorgio Palù Cristina Parolin Enzo Di Iorio |
author_sort |
Vanessa Barbaro |
title |
Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome |
title_short |
Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome |
title_full |
Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome |
title_fullStr |
Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome |
title_full_unstemmed |
Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome |
title_sort |
personalized stem cell therapy to correct corneal defects due to a unique homozygous‐heterozygous mosaicism of ectrodactyly‐ectodermal dysplasia‐clefting syndrome |
publisher |
Wiley |
series |
Stem Cells Translational Medicine |
issn |
2157-6564 2157-6580 |
publishDate |
2016-08-01 |
description |
Ectrodactyly‐ectodermal dysplasia‐clefting (EEC) syndrome is a rare autosomal dominant disease caused by mutations in the p63 gene. To date, approximately 40 different p63 mutations have been identified, all heterozygous. No definitive treatments are available to counteract and resolve the progressive corneal degeneration due to a premature aging of limbal epithelial stem cells. Here, we describe a unique case of a young female patient, aged 18 years, with EEC and corneal dysfunction, who was, surprisingly, homozygous for a novel and de novo R311K missense mutation in the p63 gene. A detailed analysis of the degree of somatic mosaicism in leukocytes from peripheral blood and oral mucosal epithelial stem cells (OMESCs) from biopsies of buccal mucosa showed that approximately 80% were homozygous mutant cells and 20% were heterozygous. Cytogenetic and molecular analyses excluded genomic alterations, thus suggesting a de novo mutation followed by an allelic gene conversion of the wild‐type allele by de novo mutant allele as a possible mechanism to explain the homozygous condition. R311K‐p63 OMESCs were expanded in vitro and heterozygous holoclones selected following clonal analysis. These R311K‐p63 OMESCs were able to generate well‐organized and stratified epithelia in vitro, resembling the features of healthy tissues. This study supports the rationale for the development of cultured autologous oral mucosal epithelial stem cell sheets obtained by selected heterozygous R311K‐p63 stem cells, as an effective and personalized therapy for reconstructing the ocular surface of this unique case of EEC syndrome, thus bypassing gene therapy approaches. Significance This case demonstrates that in a somatic mosaicism context, a novel homozygous mutation in the p63 gene can arise as a consequence of an allelic gene conversion event, subsequent to a de novo mutation. The heterozygous mutant R311K‐p63 stem cells can be isolated by means of clonal analysis and given their good regenerative capacity, they may be used to successfully correct the corneal defects present in this unique case of ectrodactyly‐ectodermal dysplasia‐clefting syndrome. |
topic |
Ectrodactyly-ectodermal dysplasia-clefting syndrome Cell therapy p63 Mosaicism Gene conversion |
url |
https://doi.org/10.5966/sctm.2015-0358 |
work_keys_str_mv |
AT vanessabarbaro personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT annamariaassuntanasti personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT paoloraffa personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT angelomigliorati personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT patrizianespeca personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT stefanoferrari personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT elisapalumbo personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT marinabertolin personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT claudiabreda personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT francescomiceli personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT antonellarusso personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT lucianacaenazzo personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT diegoponzin personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT giorgiopalu personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT cristinaparolin personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome AT enzodiiorio personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome |
_version_ |
1725017596182396928 |